{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54","upperLimit":"82","value":"67"},{"groupId":"OG001","lowerLimit":"45","upperLimit":"78","value":"59"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"description":"The event is death from any cause, patients alive at the time of last observation are considered censored.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients","id":"OG000","title":"Auto-Auto High Risk"},{"description":"Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients","id":"OG001","title":"Auto-Allo High Risk"}],"paramType":"NUMBER","populationDescription":"Patients that completed second transplant","reportingStatus":"POSTED","timeFrame":"Year 3","title":"Overall Survival (OS) for High Risk","type":"SECONDARY","unitOfMeasure":"percentage of participants"}